Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This randomized pilot clinical trial is studying the side effects and how well giving
temozolomide and cixutumumab together with combination chemotherapy works in treating
patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Giving
temozolomide and cixutumumab together with combination chemotherapy may kill more tumor
cells.